QualityDipStocks / Health Care · Hospitals
The Ensign Group ENSG
Outside our quality screen, so we don’t track its dips. It’s 16% below its 52-week high.
Outside our quality screen. No fair value estimate for now: there isn’t enough data.
- Fair value est.
- n/a
- Market Value
- forming
- Off 52-wk high
- −16%
- Risk vs market
- Lowbeta −0.05
5 bullish · 5 bearish See why
Key levels
Every level vs today’s $181.52
- 52-wk lowlowest close, 1 year$147.13−18.9%
- PriceFri Oct 30 close$181.52you are here
- 52-wk highhighest close, 1 year$215.83+18.9%
Fair value estimate
No estimate for ENSG: Capital spending isn't tagged for the latest period in SEC XBRL data. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much ENSG moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 2.3× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- -0.05
- Volatility
- 30% vs 13% SPY
- Correlation SPY
- −0.02
- Correlation QQQ
- −0.15
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
GrowthSales compounded 19% a year from FY2022 to FY2025.
GrowthSales grew 17% to $5.7B over the last 12 months vs the 12 months before (SEC filings).
ProfitabilityReturn on invested capital of 16%, above the 9.5% discount rate our DCF uses.
ProfitabilityReturn on equity of 17% over the last 12 months.
Balance sheetNet cash of $193M: cash and short-term investments exceed debt (Sep 30, 2026).
Top bearish points 5 of 5
ProfitabilityGross margin of 21%, below the 65% median for the 81 Health Care companies we cover.
Cash returnsDividend yield of 0.1%, below the 1.1% median for the 47 Health Care companies we cover.
Cash returnsShare count up 0.6% over 12 months, above the −1.0% median for the 93 Health Care companies we cover.
ProfitabilityOperating margin of 9.0%, below the 13% median for the 89 Health Care companies we cover.
QualityDoesn’t pass our quality screen: net debt 3.1× EBITDA (limit 3×).
Who’s talking about it
Notable investors, executives, analysts and public figures on The Ensign Group in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Hospitals
All fundamentals
P/E 27.3 · ROE 17% · Sales +17%
Valuation
- P/E
- 27.3×Health Care median 29.2×
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- 17.0×
- Price / sales
- 1.92×
- Price / book
- 4.26×
- Market cap
- $10.9Blisted
- Enterprise value
- $10.7B
Growth
- Revenue, 12 months
- $5.7B
- Sales growth, 12 months
- +17.5%vs the 12 months before
- Sales growth, 3 yrs
- +18.7%/yrfrom FY2022
- Diluted EPS, 12 months
- $6.72
- EPS growth, last FY
- +14.1%
- Net income, 12 months
- $399M
- Net income growth
- +22%12 months vs before
Profitability
- Gross margin
- 21.2%
- Operating margin
- 9.0%
- Net margin
- 7.0%
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- 17%
- Return on invested capital
- 16%
Balance sheet
- Cash & short-term inv.
- $392M
- Total debt
- $199M
- Net cash
- $193M
- Debt / equity
- 0.08×
- Interest coverage
- 62.8×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0.14%$15M paid
- Payout ratio
- 4%
- Buybacks, 12 months
- $47M0.4% of market cap
- Share count, 1 year
- +0.6%diluted shares vs a year ago
- Stock-based comp
- $62M
Trailing 12 months to Sep 30, 2026; balance sheet at Sep 30, 2026. From The Ensign Group’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
FCF value $154.04
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 56 · 5 days +3.4%
The business
FCF $0.4B · Sales +14%
- Free cash flow, 12 months$0.4B
- Free-cash-flow yield3.4%
- Free-cash-flow margin7%
- Gross margin17%
- Operating margin9%
- Return on invested capital9%
- Return on equity17%
- Sales growth (latest quarter vs year-ago quarter)+14%
- Net debt / EBITDA3.0×
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
ENSG is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.